Wall Street brokerages expect KemPharm, Inc. (NASDAQ:KMPH) to report earnings of ($0.69) per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for KemPharm’s earnings, with the lowest EPS estimate coming in at ($0.71) and the highest estimate coming in at ($0.67). KemPharm posted earnings of ($0.92) per share in the same quarter last year, which indicates a positive year over year growth rate of 25%. The company is scheduled to announce its next quarterly earnings report on Wednesday, November 8th.

According to Zacks, analysts expect that KemPharm will report full year earnings of ($2.70) per share for the current financial year, with EPS estimates ranging from ($2.76) to ($2.65). For the next financial year, analysts forecast that the firm will report earnings of ($2.61) per share, with EPS estimates ranging from ($2.65) to ($2.57). Zacks Investment Research’s EPS calculations are an average based on a survey of research firms that that provide coverage for KemPharm.

KemPharm (NASDAQ:KMPH) last released its quarterly earnings results on Thursday, August 10th. The specialty pharmaceutical company reported ($0.44) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.63) by $0.19.

A number of equities analysts have recently weighed in on the company. ValuEngine raised KemPharm from a “strong sell” rating to a “sell” rating in a report on Monday, October 23rd. Zacks Investment Research upgraded KemPharm from a “sell” rating to a “hold” rating in a research note on Wednesday, July 12th. Oppenheimer Holdings, Inc. set a $13.00 target price on KemPharm and gave the company a “buy” rating in a research note on Thursday, August 10th. Finally, Canaccord Genuity reiterated a “buy” rating and issued a $7.00 target price on shares of KemPharm in a research note on Monday, September 11th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $9.00.

KemPharm (NASDAQ KMPH) traded up $0.15 during midday trading on Friday, hitting $3.80. The stock had a trading volume of 50,227 shares, compared to its average volume of 26,272. KemPharm has a 12 month low of $2.45 and a 12 month high of $5.40. The company has a quick ratio of 8.40, a current ratio of 8.40 and a debt-to-equity ratio of -2.34.

In related news, major shareholder Delaware Street Capital Master bought 325,888 shares of the firm’s stock in a transaction dated Thursday, September 14th. The stock was bought at an average price of $3.27 per share, with a total value of $1,065,653.76. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In the last three months, insiders have acquired 335,188 shares of company stock valued at $1,090,088. 22.80% of the stock is owned by company insiders.

A hedge fund recently raised its stake in KemPharm stock. Bank of New York Mellon Corp lifted its stake in KemPharm, Inc. (NASDAQ:KMPH) by 17.6% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 22,854 shares of the specialty pharmaceutical company’s stock after buying an additional 3,414 shares during the period. Bank of New York Mellon Corp owned approximately 0.16% of KemPharm worth $112,000 as of its most recent SEC filing. Institutional investors own 40.01% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “-$0.69 Earnings Per Share Expected for KemPharm, Inc. (KMPH) This Quarter” was originally published by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The legal version of this report can be accessed at https://www.americanbankingnews.com/2017/11/04/0-69-earnings-per-share-expected-for-kempharm-inc-kmph-this-quarter.html.

About KemPharm

KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP).

Get a free copy of the Zacks research report on KemPharm (KMPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for KemPharm Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm Inc. and related companies with MarketBeat.com's FREE daily email newsletter.